Literature DB >> 8955168

IL-16 inhibition of CD3-dependent lymphocyte activation and proliferation.

W W Cruikshank1, K Lim, A C Theodore, J Cook, G Fine, P F Weller, D M Center.   

Abstract

We have recently described the cDNA and predicted protein structure of a natural soluble CD4 ligand, IL-16. IL-16 is chemotactic for CD4+ T cells and induces functional IL-2 receptors in CD4+ T cells. The binding of IL-16 to CD4 results in activation of p56(lck), whose adaptor function is essential for the chemotactic response. Subsequently, increases in intracellular Ca2+ and phosphatidylinositol 1,4,5-trisphosphate occur, as does translocation of protein kinase C from cytosol to membrane. Because of the similarities between these signals and functions and those noted for the CD4 ligand HIV-1 gp120, we investigated the potential regulatory effects of IL-16 on CD3/TCR-mediated lymphocyte activation. Preincubation of human T cells with IL-16 up to 24 h before activation with plate-bound anti-CD3 Abs reduced T cell activation by 80%, as monitored by IL-2R expression and [3H]thymidine uptake. If IL-16 was added following anti-CD3 activation, no suppression was noted. The suppressive effects of preincubation with IL-16 were not rescued by the addition of rIL-2 and were not the result of priming for anti-CD3-induced apoptosis. In addition, IL-16 had no effect on surface expression of CD3 or CD4. However, IL-16 did reduce the magnitude of the anti-CD3-induced intracellular Ca2+ increase. These studies indicate that while the interaction of CD4 with its natural ligand, IL-16, results in Ag-independent chemotaxis and IL-2R expression, this pro-inflammatory state is associated with subsequent transient inhibition of responsiveness via the CD3/TCR complex.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8955168

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

1.  Increased levels of interleukin-16 in the airways of tobacco smokers: relationship with peripheral blood T lymphocytes.

Authors:  M Laan; I Qvarfordt; G C Riise; B A Andersson; S Larsson; A Lindén
Journal:  Thorax       Date:  1999-10       Impact factor: 9.139

2.  Impaired survival of T helper cells in the absence of CD4.

Authors:  J Strong; Q Wang; N Killeen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-20       Impact factor: 11.205

3.  alpha2-macroglobulin modulates the immunoregulatory function of the lipocalin placental protein 14.

Authors:  G J Riely; J Rachmilewitz; P H Koo; M L Tykocinski
Journal:  Biochem J       Date:  2000-10-15       Impact factor: 3.857

4.  Cutting edge: CD4 is the receptor for the tick saliva immunosuppressor, Salp15.

Authors:  Renu Garg; Ignacio J Juncadella; Nandhini Ramamoorthi; Shobana K Ananthanarayanan; Venetta Thomas; Mercedes Rincón; Joanna K Krueger; Erol Fikrig; Christopher M Yengo; Juan Anguita
Journal:  J Immunol       Date:  2006-11-15       Impact factor: 5.422

5.  Cells, cytokines, chemokines, and cancer stress: A biobehavioral study of patients with chronic lymphocytic leukemia.

Authors:  Barbara L Andersen; Neha Godiwala Goyal; David M Weiss; Travis D Westbrook; Kami J Maddocks; John C Byrd; Amy J Johnson
Journal:  Cancer       Date:  2018-05-14       Impact factor: 6.860

6.  Recombinant human IL-16 inhibits HIV-1 replication and protects against activation-induced cell death (AICD).

Authors:  T Idziorek; J Khalife; O Billaut-Mulot; E Hermann; M Aumercier; Y Mouton; A Capron; G M Bahr
Journal:  Clin Exp Immunol       Date:  1998-04       Impact factor: 4.330

7.  The role of interleukin-16 in murine contact hypersensitivity.

Authors:  K Masuda; N Katoh; F Soga; S Kishimoto
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

8.  GA-binding protein factors, in concert with the coactivator CREB binding protein/p300, control the induction of the interleukin 16 promoter in T lymphocytes.

Authors:  N Bannert; A Avots; M Baier; E Serfling; R Kurth
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

9.  IL-16 in the airways of lung allograft recipients with acute rejection or obliterative bronchiolitis.

Authors:  M Laan; A Lindén; G C Riise
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

10.  Human mid-gestation amniotic fluid contains interleukin-16 bioactivity.

Authors:  Catherine A Thornton; Judith A Holloway; Janis K Shute; John W Holloway; Norma D Diaper; John O Warner
Journal:  Immunology       Date:  2009-04       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.